PRAX
Praxis Precision Medicines, Inc.
17.31
USD
This page is just a preview of the data found in TrendSpider’s full version
Praxis Precision Medicines, Inc. stock is up 3.1% since 30 days ago. The next earnings date is Feb 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 December’s closed higher than November. 100% of analysts rate it a buy.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression.
